ArticleCurrent addiction reports2023
Metabolic profiles associated with opioid use and opioid use disorder: a narrative review of the literature.
Article in Current addiction reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 12 citations in OpenAlex.
- Adiposity and inflammation mediate altered metabolic profile in individuals with opioid use disorder.Journal of psychiatric research · 2026Article
- GLP-1 Receptor Agonist Treatment and Health Outcomes in Methadone-Treated Patients with Opioid Use Disorder and Diabetes.Journal of general internal medicine · 2026Article
- Adiposity and inflammation mediate altered metabolic profiles in individuals with opioid use disorder.medRxiv : the preprint server for health sciences · 2026Article
- Effect of EEG-guided opioid-free anesthesia on perioperative blood glucose variation in patients undergoing video-assisted thoracic surgery: a secondary analysis of a randomized controlled study.Perioperative medicine (London, England) · 2026Article
- Maternal Opioids Downregulate Adiponectin Receptor Signaling and Alter Growth in Offspring: Pilot Study.medRxiv : the preprint server for health sciences · 2026Article
- Maternal opioids downregulate adiponectin receptor signaling and alter growth in offspring: pilot study.Frontiers in pediatrics · 2026Article
- Perinatal morphine exposure induces chromatin and transcriptomic remodeling to alter immune and metabolic function.Frontiers in immunology · 2026Article
- Family-centered education vs telephone follow-up on nutrition pattern and Body Mass Index of opioid-dependent patients: A quasi-experimental study.Addiction & health · 2026Article
- The Police Opioid Seizure Temporal Risk (POSTeR) model of increased exposure to fatal overdose.The International journal on drug policy · 2025Article
- Assessment of laparotomy-induced stress response in opium- and morphine-addicted rats by measuring serum glucose and corticosterone levels: an animal experiment.Annals of medicine and surgery (2012) · 2025Article
- Platelet/high-density lipoprotein cholesterol ratio as a biomarker of depression in individuals with chronic opioid use.Frontiers in psychiatry · 2025Article
- Association between body mass index and treatment completion in extended-release naltrexone-treated patients with opioid dependence.Frontiers in psychiatry · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Purpose of Review: Opioid use disorder (OUD) is a chronic, relapsing condition that is epidemic in the USA. OUD is associated with serious adverse consequences, including higher incarceration rates, impaired medical and mental health, and overdose-related fatalities. Several medications with demonstrated clinical efficacy in reducing opioid use are approved to treat OUD. However, there is evidence that medications for OUD cause metabolic impairments, which raises concerns over the long-term metabolic health of individuals recovering from OUD. Here, we summarize the scientific literature on the metabolic effects of the use of opioids, including medications for treating OUD. Recent Findings: Our findings showed lower body weight and adiposity, and better lipid profiles in individuals with OUD. In individuals with diabetes mellitus, opioid use was associated with lower blood glucose levels. In contrast, among individuals without underlying metabolic conditions, opioids promoted insulin resistance. Treatment of OUD patients with the agonists methadone or buprenorphine caused weight gain, increased liking and intake of sugar, and impaired lipid profile and glucose metabolism, whereas treatment with the antagonist naltrexone demonstrated evidence for reduced sweet preferences. Summary: Our findings highlighted a gap in knowledge regarding the safety of medications for OUD. Further research is needed to determine how best to reduce the risk of metabolic disorder in the treatment of OUD with opioid agonists versus antagonists.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.